yahoo_financeOriginal article
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Trial StartPaxalisibPositive
AI Analysis
Summary
Kazia Therapeutics has dosed the first patient in the PNOC035 clinical study evaluating paxalisib for recurrent pediatric AT/RT brain cancer, marking an advancement in the trial's execution.
Clinical Trial Data
NCT ID
Outcome Details
First patient dosed in PNOC035 clinical study
Importance:5/10
Sentiment:
0.50
pediatric oncologybrain cancerclinical trialpatient enrollment
Related Companies
Read the original article
Published by yahoo_finance on September 9, 2026 11:30 AM